Doctor in consultation

OMJJARA▼ (momelotinib) find your representative

Want to know more? Get in touch with your local OMJJARA GSK Key Account Manager today

Find your local representative

Map of UK sales representative territories Map of UK sales representative territories
Matthew Griffin

Matthew Griffin

National Sales Manager
07795576506

matthew.e.griffin@gsk.com

Summary of product characteristics & Patient information leaflet for 100 mg

Summary of product characteristics & Patient information leaflet for 150 mg

Summary of product characteristics & Patient information leaflet for 200 mg

INDICATION

Omjjara ▼ (momelotinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (MF), post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis and who are:
1. Janus Kinase (JAK) inhibitor naïve
or
2. Have been treated with ruxolitinib.1

Reference

  1. OMJJARA UK, SmPC.

▶︎ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to GSK on 0800 221 441, via email: uksafety@gsk.com or at https://gsk.public.reportum.com/

November 2026 | PM-GB-MML-WCNT-260016 (v1.0)